Abstract
Nasopharyngeal carcinoma (NPC) causes severe oncogenic lesions in the nasopharynx. CD47, a transmembrane integrin-associated protein, plays a key role in the ability of tumor cells to escape phagocytosis, working as an immune checkpoint in the immune response. Besides this role, CD47 has been reported to regulate cell proliferation and migration. The present study addresses the relationship between CD47 and microRNA-200a and examines their regulatory mechanisms in NPC. Bioinformatics analyses and dual-luciferase reporter assays were used to confirm the putative relationship between miR-200a and CD47, and their interaction was further detected using western blotting and RT-PCR. Further, results showed that miR-200a affect NPC cell proliferation, migration, and invasion by regulating CD47. A cell phagocytosis assay showed that miR-200a and a CD47 monoclonal antibody increased the sensitivity of NPC cells to macrophage phagocytosis by inhibiting the functions of CD47. Additionally, miR-200a expression was suppressed and CD47 expression increased in both clinical NPC tissues and cell lines. Taken together, these results show the miR-200a/CD47 combination as a potential therapeutic for treatment of NPC.
References
Apr 3, 2001·The Journal of Experimental Medicine·P A OldenborgF P Lindberg
Jan 28, 2004·Cell·David P Bartel
Jul 28, 2009·Cell·Ravindra MajetiIrving L Weissman
Nov 26, 2009·Biochemical and Biophysical Research Communications·Hongping XiaMarie C Lin
May 11, 2010·Trends in Immunology·Siddhartha JaiswalIrving L Weissman
May 20, 2011·Auris, Nasus, Larynx·Tomokazu YoshizakiKazuhira Endo
Dec 7, 2011·Molecular and Cellular Biology·Sarah JurmeisterÖzgür Sahin
May 30, 2012·Oncology Reports·Shigemasa SuzukiHiroyuki Kuwano
Feb 14, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Terence Kin-Wah LeeIrene Oi Lin Ng
Mar 19, 2014·Urologic Oncology·Thomas HofnerMartin R Sprick
May 27, 2014·Oncogene·O SenolO Saydam
Oct 29, 2014·Nature Communications·Limo ChenF Xiao-Feng Qin
Mar 15, 2015·Seminars in Diagnostic Pathology·Fredrik Petersson
Jun 17, 2015·Cancer Medicine·Kazumichi YoshidaKazuo Hase
Sep 1, 2015·Lancet·Melvin L K ChuaAnthony T C Chan
Oct 30, 2015·Proceedings of the National Academy of Sciences of the United States of America·Huimin ZhangGregg L Semenza
Feb 3, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·F KongY Jia
Feb 4, 2016·Oncotarget·Sukhbir KaurDavid D Roberts
Feb 5, 2016·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Xiao-Fang LiuHuan Yang
Apr 12, 2016·Journal of Translational Medicine·Margherita GiganteElena Ranieri
May 6, 2016·Nature Communications·Shaohua XuKe Chen
Sep 30, 2016·Proceedings of the National Academy of Sciences of the United States of America·Alissa C RothchildAlan Aderem
Mar 14, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kipp Weiskopf
Jan 9, 2018·Oncoimmunology·Feng LiXiaodan Jiang
Jan 18, 2018·Trends in Immunology·André Veillette, Jun Chen
Jan 26, 2018·Molecular Cancer·Wei HuangYue-Qin Chen
Feb 2, 2018·International Journal of Cancer. Journal International Du Cancer·Stephen J O'BrienSusan Galandiuk
May 30, 2019·BMC Cancer·Feng JiangQichun Wei
Jun 12, 2019·Cancer Medicine·Hongcheng YangYing Lin